𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Brain atrophy in Huntington's disease

✍ Scribed by S. E. Starkstein; S. E. Folstein; J. Brandt; G. D. Pearlson; A. McDonnell; M. Folstein

Publisher
Springer
Year
1989
Tongue
English
Weight
378 KB
Volume
31
Category
Article
ISSN
0028-3940

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

The topographic distribution of brain at
The topographic distribution of brain atrophy in Huntington's disease and progressive supranuclear palsy
✍ D. M. A. Mann; R. Oliver; J. S. Snowden πŸ“‚ Article πŸ“… 1993 πŸ› Springer-Verlag 🌐 English βš– 717 KB

The topographic distribution of brain atrophy was quantified by image analysis of fixed coronal brain slices from 12 patients dying with Huntington's disease (HD) and from 4 other patients dying with progressive supranuclear palsy (PSP). In HD, atrophy was maximal within the caudate nucleus, putamen

Rate and acceleration of whole-brain atr
Rate and acceleration of whole-brain atrophy in premanifest and early Huntington's disease
✍ Edward J. Wild; Susie M.D. Henley; Nicola Z. Hobbs; Chris Frost; David G. MacMan πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 219 KB πŸ‘ 1 views

Huntington's disease (HD) produces progressive and ultimately widespread impairment of brain function. Neostriatal atrophy alone cannot account for whole-brain losses seen postmortem, and the mutant huntingtin protein and its neuropathologic sequelae are evident throughout the brain. Whole-brain atr

Whole-brain atrophy as a measure of prog
Whole-brain atrophy as a measure of progression in premanifest and early Huntington's disease
✍ Susie M.D. Henley; Edward J. Wild; Nicola Z. Hobbs; Chris Frost; David G. MacMan πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 305 KB πŸ‘ 1 views

## Abstract Therapeutic trials in Huntington's disease (HD) are challenging as clinical progression is slow and variable and reliable biomarkers are lacking. We used magnetic resonance imaging and the brain boundary shift integral to quantify whole‐brain atrophy rates over 1 year in early and prema